Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | USP2 | O75604 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
| ▸ | CASP7 | P55210 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5943042 | 0.94 | CNR1 (0.40) | CYP1A2USP2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL4680959 | 0.74 | PTGDR2 (0.42) | CNR1ALDH1A1PTGER1DHODHEGLN1 | |
| SCHEMBL4807874 | 0.72 | CNR1 (0.47) | CYP1A2USP2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL5943078 | 0.71 | CNR1 (0.46) | CNR1KDM4ELMNAMAPTL3MBTL1 | |
| SCHEMBL10512344 | 0.71 | CNR1 (0.42) | CYP1A2USP2CYP3A4CYP2C9CNR1 | |
| SCHEMBL4677242 | 0.71 | CNR1 (0.46) | CNR1ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL10512191 | 0.70 | L3MBTL1 (0.49) | CYP1A2USP2CYP3A4CYP2C9CNR1 | |
| SCHEMBL10444974 | 0.70 | LMNA (0.49) | CYP1A2CYP3A4CYP2C9CNR1ALDH1A1 | |
| SCHEMBL5211789 | 0.69 | ADORA1 (0.42) | CNR1HSD17B10NPC1 | |
| SCHEMBL12077243 | 0.69 | ADORA1 (0.42) | CYP1A2CYP3A4CYP2C9MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135523-A1 | 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | US | claimed |
| EP-1641779-A1 | 2-SUBSTITUED 5, 6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATOR. | AstraZeneca AB (SE) | 2006-04-05 | — | — | EP | claimed |
| WO-2004111033-A1 | 2-SUBSTITUED 5, 6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATOR. | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | claimed |
| US-20060135523-A1 | 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | US | disclosed |
| EP-1641779-A1 | 2-SUBSTITUED 5, 6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATOR. | AstraZeneca AB (SE) | 2006-04-05 | — | — | EP | disclosed |
| WO-2004111033-A1 | 2-SUBSTITUED 5, 6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATOR. | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135523-A1 | 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator | CNR2, CNR1, GPR55 | CYP1A2 533/4885USP2 1021/4885CYP3A4 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.